Navigation Links
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results
Date:3/3/2011

SAN DIEGO, March 3, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced it expects to report fourth quarter and full year 2010 financial results after the NASDAQ Global Market closes on Thursday, March 10, 2011.  The Company also expects to host a conference call that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and highlights for the fourth quarter and full year 2010, as well as provide a corporate update.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

The conference call may be accessed by dialing (877) 280-7280 for domestic callers and (678) 825-8232 for international callers. Please specify to the operator that you would like to join "Optimer's Financial Results Call."  The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com, where it will be archived for 30 days following the call.  Please connect to Optimer's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.  

About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of fidaxomicin, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com. ContactsOptimer Pharmaceuticals, Inc.Christina Donaghy, Corporate Communications ManagerJohn D. Prunty, Chief Financial Officer & VP Finance858-909-0736Canale CommunicationsJason I. Spark, Senior Vice President619-849-6005
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
2. Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
3. Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
4. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
5. Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI)
6. Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
7. Optimer Pharmaceuticals Announces Key Additions to Management Team
8. Optimer Pharmaceuticals Obtains Additional Fidaxomicin Patent
9. Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection
10. Optimer Pharmaceuticals Appoints Gregory Papaz to New Position of Senior Vice President of Commercial Operations
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... de marzo de 2017   VWR ... soluciones de productos y servicios para clientes de ... adquirido EPL Archives, Inc., una organización de servicios ... todo el ciclo de vida de investigación de ... de archivo, almacenamiento de documentos y servicios complementarios. ...
(Date:3/22/2017)... 22, 2017 Ampio Pharmaceuticals, Inc. (NYSE ... Ampion™, a low molecular weight fraction of human ... it is re-issuing its previous release that was made ... that are required under the NYSE MKT Company ... additional disclosures along with the previously disclosed update ...
(Date:3/22/2017)... New Jersey,s hospitals ... and saved $641 million in healthcare costs between 2012 ... quality improvement program. The results reflect ... part of a national initiative from the U.S. Department ... Jersey Hospital Association and its affiliate, the Health Research ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... 23, 2017 , ... Natural Subsistence, a company known for ... and nutrition, announced its product Leyzene is now available for purchase on Go4ItNutrition.com, ... that help people improve all aspects of their health so they can live ...
(Date:3/23/2017)... ... March 23, 2017 , ... The American Board of ... the 40th Anniversary of ABQAURP’s dedication to Health Care Quality and Management and Patient ... contributed not only to the association, but also to the Health Care Quality and ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... with European Guidelines and the New MEDDEV 2.7/1 Rev. 4 Guidance, **An ... http://www.fdanews.com/mdclineval                  , How will the new EU MDR language change ...
(Date:3/23/2017)... ... March 23, 2017 , ... “Beyond and Back”: a true-life testimony of tragedy ... of published author Bonetta Rose, a wife, mother and grandmother committed to sharing her ... Faith Publishing, Bonetta Rose‘s new book presents actual events in the life of her ...
(Date:3/23/2017)... ... March 23, 2017 , ... “A Respectful ... “A Respectful Response To Atheist Manifesto” is the creation of published author Richard ... Nancy, for sixty years. He holds graduate degrees from Kent State University and ...
Breaking Medicine News(10 mins):